Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox

Detalles Bibliográficos
Autores principales: Javanmard, Shaghayegh Haghjooy, Heshmat-Ghahdarijani, Kiyan, Vaseghi, Golnaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235302/
https://www.ncbi.nlm.nih.gov/pubmed/32362297
http://dx.doi.org/10.1017/ice.2020.195
_version_ 1783535936636715008
author Javanmard, Shaghayegh Haghjooy
Heshmat-Ghahdarijani, Kiyan
Vaseghi, Golnaz
author_facet Javanmard, Shaghayegh Haghjooy
Heshmat-Ghahdarijani, Kiyan
Vaseghi, Golnaz
author_sort Javanmard, Shaghayegh Haghjooy
collection PubMed
description
format Online
Article
Text
id pubmed-7235302
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-72353022020-05-20 Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox Javanmard, Shaghayegh Haghjooy Heshmat-Ghahdarijani, Kiyan Vaseghi, Golnaz Infect Control Hosp Epidemiol Letter to the Editor Cambridge University Press 2020-05-04 /pmc/articles/PMC7235302/ /pubmed/32362297 http://dx.doi.org/10.1017/ice.2020.195 Text en © The Society for Healthcare Epidemiology of America 2020 http://creativecommons.org/licenses/by/4.0/ This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Javanmard, Shaghayegh Haghjooy
Heshmat-Ghahdarijani, Kiyan
Vaseghi, Golnaz
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
title Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
title_full Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
title_fullStr Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
title_full_unstemmed Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
title_short Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
title_sort angiotensin-converting-enzyme inhibitors (ace inhibitors) and angiotensin ii receptor blocker (arb) use in covid-19 prevention or treatment: a paradox
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235302/
https://www.ncbi.nlm.nih.gov/pubmed/32362297
http://dx.doi.org/10.1017/ice.2020.195
work_keys_str_mv AT javanmardshaghayeghhaghjooy angiotensinconvertingenzymeinhibitorsaceinhibitorsandangiotensiniireceptorblockerarbuseincovid19preventionortreatmentaparadox
AT heshmatghahdarijanikiyan angiotensinconvertingenzymeinhibitorsaceinhibitorsandangiotensiniireceptorblockerarbuseincovid19preventionortreatmentaparadox
AT vaseghigolnaz angiotensinconvertingenzymeinhibitorsaceinhibitorsandangiotensiniireceptorblockerarbuseincovid19preventionortreatmentaparadox

Ejemplares similares